Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy - Takeaways - MDSpire

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy

  • By

  • M. Korenkov

  • J. Liebaert

  • S. Yousefian

  • S. Schwartz

  • U. M. Demel

  • J. Braune

  • M. C. Odabasi

  • L. Herzberg

  • D. Böckle

  • N. C. Görür

  • V. v. Landenberg-Roberg

  • S. Bohl

  • E. Tregel

  • S. Hennig

  • C. Franke

  • S. Haas

  • U. Keller

  • J. Krönke

  • A. Busse

  • October 20, 2025

  • 0 min

Share

  • 1

    Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy approved for relapsed/refractory multiple myeloma.

  • 2

    Chronic inflammatory demyelinating polyneuropathy (CIDP) can occur post-cilta-cel therapy, presenting as progressive motor and sensory deficits.

  • 3

    Two patients developed CIDP after cilta-cel infusion, with one experiencing severe neurological decline and the other showing gradual improvement.

  • 4

    Both patients required intensive treatment, including high-dose dexamethasone and cyclophosphamide, to manage CIDP symptoms.

  • 5

    Patient 2 improved significantly after treatment, while Patient 1 succumbed to progressive neurological deterioration and infections.

Original Source(s)

Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy

  • by M. Korenkov, J. Liebaert, S. Yousefian, S. Schwartz, U. M. Demel, J. Braune, M. C. Odabasi, L. Herzberg, D. Böckle, N. C. Görür, V. v. Landenberg-Roberg, S. Bohl, E. Tregel, S. Hennig, C. Franke, S. Haas, U. Keller, J. Krönke, A. Busse

  • October 20, 2025

Related Content

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Editorial: A new perspective on the importance of dendritic cells in cancer immunity: from bench to patient’s bedside